Metraipolis › archive › dc_1005aee5cfbf
An engineered anti-Oropouche virus human-murine chimeric immunoglobulin M is a viable substitute for positive human serum controls in diagnostic serology assays — Europe PMC PMID:42574484
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42574484
- DOI
- 10.1371/journal.pntd.0014642
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T07:55:27.884Z
- SHA-256 of the archived text
213b7c77139552ac16ebf623a9220ebecbc112f798e3cec34a6f25044de6f896- Stable URL of this page
https://metraipolis.com/documento/dc_1005aee5cfbf
How to cite
An engineered anti-Oropouche virus human-murine chimeric immunoglobulin M is a viable substitute for positive human serum controls in diagnostic serology assays — Europe PMC PMID:42574484 — Europe PMC (en), https://europepmc.org/article/MED/42574484 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_1005aee5cfbf (Metraipolis archive dc_1005aee5cfbf, sha256 213b7c77139552ac16ebf623a9220ebecbc112f798e3cec34a6f25044de6f896)
BibTeX
@misc{dc1005aee5cfbf,
title = {An engineered anti-Oropouche virus human-murine chimeric immunoglobulin M is a viable substitute for positive human serum controls in diagnostic serology assays — Europe PMC PMID:42574484},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42574484},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_1005aee5cfbf; sha256 213b7c77139552ac16ebf623a9220ebecbc112f798e3cec34a6f25044de6f896},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/42574484. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Oropouche virus (OROV) is an arbovirus of concern due to its recent geographical expansion and association with teratogenic outcomes. Serodiagnosis of OROV infection relies on methods such as the immunoglobulin M antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) and the plaque reduction neutralization test (PRNT). For re-emerging viruses such as OROV, sourcing large quantities of sera from acutely infected human donors for use as positive-control assay material is a significant challenge and hinders diagnostic capacity. To overcome this, we engineered and produced OROV119-chIgM, a human-murine chimeric IgM (chIgM) that expresses the variable regions of the murine monoclonal antibody OROV119, reactive to the Gc protein of OROV, on a human IgM backbone. OROV119-chIgM was evaluated in PRNT and MAC-ELISA to determine its suitability as a positive control in each assay. In PRNT, OROV119-chIgM achieved neutralization equivalent to an OROV polyclonal mouse hyperimmune ascitic fluid (MHIAF). Further, OROV119-chIgM exhibited superior performance compared with OROV-positive human donor sera in a MAC-ELISA. Overall, OROV119-chIgM is an attractive alternative to human donor sera assay control material because of its long-term sustainability and consistent batch-to-batch potency. OROV119-chIgM enhances diagnostic capacity by ensuring laboratories are poised to respond rapidly to future OROV outbreaks. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS neglected tropical diseases, 2026 (prima pubblicazione 2026-08-10). Identificativi: PMID 42574484 · PMCID PMC13475966 · DOI 10.1371/journal.pntd.0014642. Descrittori MeSH principali: Orthobunyavirus; Bunyaviridae Infections; Immunoglobulin M; Antibodies, Viral; Serologic Tests. Pagina: https://europepmc.org/article/MED/42574484 — https://doi.org/10.1371/journal.pntd.0014642. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T07:47:50.156Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.